“Shire reported 4Q17 results and provided its 2018 financial guidance this morning. The report was mixed relative to expectations. Investors that we spoke with were anticipating a strong 4Q17 with no surprises, but hoping for 2018 consensus sales and EPS that would at least bracket consensus (which did not happen).”,” Cantor Fitzgerald’s analyst commented.
Several other research analysts also recently weighed in on SHPG. Sanford C. Bernstein upgraded shares of Shire from a market perform rating to an outperform rating in a research report on Wednesday. ValuEngine downgraded shares of Shire from a buy rating to a hold rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Shire from a sell rating to a hold rating in a research note on Tuesday, February 6th. BidaskClub cut shares of Shire from a hold rating to a sell rating in a research note on Wednesday, January 10th. Finally, Royal Bank of Canada set a $192.00 price objective on shares of Shire and gave the company a buy rating in a research note on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $212.50.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping the consensus estimate of $3.86 by $0.12. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $4.15 billion during the quarter. During the same quarter last year, the company earned $3.37 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. equities analysts predict that Shire will post 15 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI grew its stake in shares of Shire by 22.1% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 375 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Shire by 6.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 381 shares during the period. Pitcairn Co. grew its stake in shares of Shire by 26.5% in the 3rd quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 401 shares during the period. ETRADE Capital Management LLC lifted its holdings in shares of Shire by 6.9% in the 4th quarter. ETRADE Capital Management LLC now owns 7,212 shares of the biopharmaceutical company’s stock worth $1,119,000 after acquiring an additional 466 shares during the last quarter. Finally, Thompson Investment Management Inc. lifted its holdings in shares of Shire by 5.2% in the 3rd quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock worth $1,438,000 after acquiring an additional 468 shares during the last quarter. 20.74% of the stock is owned by institutional investors and hedge funds.
WARNING: “Shire (SHPG) PT Set at $222.00 by Cantor Fitzgerald” was originally published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.themarketsdaily.com/2018/02/15/shire-shpg-pt-set-at-222-00-by-cantor-fitzgerald.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.